Everyone snores occasionally and it’s generally not something to worry about. But if
Solifenacin
Vesicare is a medicine that regulates the activity of a bladder that is too active. The tablets are taken by people who suffer from incontinence. Vesicare extends the time between bathroom visits and increases the capacity of your bladder. Vesicare contains solifenacin. Solifenacin stops the uncontrolled contraction of the bladder wall. This reduces the need to urinate, and you have to urinate less often, and the bladder can absorb more urine before you need to urinate. The other ingredients are corn starch, milk sugar, hypromellose, magnesium stearate, macrogol, talc, titanium dioxide, and iron oxide.
the items you wish
to order
by our qualified
prescriber
to your door step
Please use the options provided to make your final selection.

Brand | Medicine Strength | Size | Price |
---|---|---|---|
Solifenacin (Generic) | 10mg | 30 Tablets | 40.00 |
Solifenacin (Generic) | 10mg | 60 Tablets | 65.00 |
Solifenacin (Generic) | 10mg | 90 Tablets | 91.00 |
Solifenacin (Generic) | 5mg | 30 Tablets | 37.00 |
Solifenacin (Generic) | 5mg | 60 Tablets | 63.00 |
Solifenacin (Generic) | 5mg | 90 Tablets | 89.00 |
Vesicare | 10mg | 30 Tablets | 61.00 |
Vesicare | 10mg | 60 Tablets | 113.00 |
Vesicare | 10mg | 90 Tablets | 159.00 |
Vesicare | 5mg | 30 Tablets | 56.00 |
Vesicare | 5mg | 60 Tablets | 103.00 |
Vesicare | 5mg | 90 Tablets | 148.00 |
It looks like you missed filling in questions from the last consultation.Click Here to submit your response.
Solifenacin is a specific competitive cholinergic receptor antagonist. The urinary bladder is innervated by parasympathetic cholinergic nerves.
Vesicare belongs to the group of anticholinergics. These medications are used to reduce the activity of an overactive bladder. This gives you more time before going to the toilet and increases the amount of urine your bladder can hold.
Solifenacin is a specific competitive cholinergic receptor antagonist. The urinary bladder is innervated by parasympathetic cholinergic nerves. Acetylcholine contracts detrusor smooth muscle through muscarinic receptors, of which the M3 subtype is predominantly involved. In vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor of M3 subtype muscarinic receptors. Furthermore, solifenacin has been shown to be a specific antagonist of muscarinic receptors, showing low or no affinity for various other receptors and for the ion channels analyzed.
Vesicare is used to treat symptoms of overactive bladder syndrome. These symptoms include: having a sudden, strong urge to urinate without warning, having to urinate frequently, or having urine leaks from not being on time for service.
Always use this medicine exactly as your doctor has told you. If in doubt, consult your doctor or pharmacist again.
You should swallow the entire tablet with some liquid. It can be taken with or without food, depending on your preference. Do not crush the tablets.
The normal dose is 5 mg a day unless your doctor tells you to take 10 mg a day.
Symptoms in case of overdose may include headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not (hallucinations), pronounced excitement, seizures, shortness of breath, increased heart rate (tachycardia), accumulation of urine in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If you forget to take Vesicare
If you forget to take a dose at the usual time, take it as soon as you remember unless it is time to take the next dose. Never take more than one dose a day. If you have any questions, always ask your doctor or pharmacist.
Like all medicines, this Genito medication can cause side effects, although not everybody gets them.
If you experience an allergy attack or severe skin reaction (for example blistering and peeling skin), you should inform your doctor or nurse immediately.
Angioedema (a skin allergy resulting in inflammation that occurs in the tissue below the skin's surface) with airway obstruction (shortness of breath) has been reported in some patients treated with solifenacin succinate (Vesicare ). If angioedema occurs, treatment with solifenacin succinate (Vesicare) should be discontinued immediately and appropriate treatment and / or appropriate measures should be taken.
Vesicare may cause the following side effects:
Very common (may affect more than 1 in 10 people)
- dry mouth
Common (may affect up to 1 in 10 people)
- blurry vision
- constipation, nausea, indigestion with symptoms such as a feeling of heaviness of the stomach, abdominal pain, belching, nausea and heartburn (dyspepsia), upset stomach
Uncommon side effects (may affect up to 1 in 100 people)
- urinary tract infection, bladder infection
- drowsiness
- abnormal perception of taste (dysgeusia)
- dry (irritated) eyes
- dry nostrils
- reflux disease (gastroesophageal reflux)
- dry throat
- Dry Skin
- Difficulty urinating
- fatigue
- fluid buildup in the lower extremities (edema)
Rare side effects (may affect up to 1 in 1,000 people)
- accumulation of large amounts of hardened stool in the large intestine (fecal impaction)
- accumulation of urine in the bladder due to the inability to empty the bladder (urinary retention)
- dizziness, headache
- vomiting
- itching, rash
Very rare side effects (may affect up to 1 in 10,000 people)
- hallucinations, confusion
- allergic skin rash.
Frequency not known (frequency cannot be estimated from the available data)
- decreased appetite, high levels of potassium in the blood that can cause an abnormal heart rhythm.
- increased pressure in the eyes
- changes in the electrical activity of the heart (ECG), irregular heartbeat, palpitations, fast heartbeat.
- voice disorder
- liver disorder
- muscular weakness
- kidney disorder
Interactions
Pharmacological interactions
Concomitant medication with other medicinal products with anticholinergic properties may lead to more pronounced therapeutic effects and adverse effects. An interval of approximately one week should be allowed after stopping Vesicare treatment before starting another anticholinergic treatment. The therapeutic effect of solifenacin can be reduced by the concomitant administration of cholinergic receptor agonists.
Solifenacin may reduce the effect of medicines that stimulate the motility of the digestive tract, such as metoclopramide and cisapride.
Pharmacokinetic interactions
In vitro studies have shown that at therapeutic concentrations, solifenacin does not inhibit CYP1A1 / 2, 2C9, 2C19, 2D6, or 3A4 enzymes derived from human liver microsomes. Therefore, solifenacin is unlikely to alter the clearance of medicinal products metabolized by such CYP enzymes.
You can buy Vesicare Solifenacin Tablets online through one of the UK’s leading online pharmacies, Pharmacy Planet. It's easy and convenient. You will need to fill out a short assessment and the item will be delivered directly to your door. If you want to buy these Genito-Urinary Tablets online, use Pharmacy Planet, a UK pharmacy you can trust.

clinical consultation
Answer a few questions on your health and your fitness goals.

assessment
Our clinicians will review your clinical questionnaire to make sure treatment is right for you.

aboard!
Once approved, you will access our wealth of experience and resources curated by our team and begin your clinical weight loss journey.
Start your journey with us
Need Help?

Start your weight loss journey heading in the right direction. Our team are here to help. Whether you’re unsure about which medicine is right for you or need help navigating the world of weight loss drugs, our team are on hand to help you make the right decision. We can put you in touch with one of our experienced weight loss clinicians so you can be sure you’re making the best decision with the most accurate information.
To get in touch, contact our Customer Service team on 0800 978 8956 or email headoffice@pharmacyplanet.com.

Authored By
HARMINDER ‘HARMY’ KAUR
BSc(hons) Pharmacy
GPhC Number: 2061107

Reviewed By
GURDEV SEHMI
BSc Pharm, MRPharmS, Independent Prescriber, Superintendent Pharmacist, Clinical Lead
GPhC Number: 2050925